At a glance
- Originator Aventis
- Class Anti-inflammatories
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Respiratory tract disorders
Most Recent Events
- 25 Feb 1999 No-Development-Reported for Respiratory tract disorders in USA (Unknown route)
- 13 Dec 1996 Preclinical development for Respiratory tract disorders in USA (Unknown route)